A Multi-center, Open-label, Multiple-dose Design, Phase 2 Trial to Evaluate the Safety and Efficacy of STSP-0601 for Injection in Patients With Hemophilia Without Inhibitor
Latest Information Update: 04 Jan 2024
At a glance
- Drugs STSP-0601 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Staidson Beijing BioPharmaceuticals
Most Recent Events
- 29 Dec 2023 Status changed from recruiting to completed.
- 18 Jan 2023 Status changed from not yet recruiting to recruiting.
- 22 Nov 2022 New trial record